Most New Drug Candidates (NCEs) fail during drug development, due to unacceptable toxicity or simply lack of evidence of efficacy on the target disease in Phase II clinical trials- III.
Dawa nyingi mpya zilizoteuliwa (NCE) huwa hazifaulu wakati wa maendeleo ya dawa, kwa sababu ina sumu isiyokubalika au kwa sababu hazithibitishi ufanisi katika ugonjwa unaolengwa, kama ilivyoonyeshwa katika vipimo vya kliniki vya Awamu ya II-III.